423 related articles for article (PubMed ID: 30616753)
1. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
3. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
4. To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases.
Onishi I; Yamamoto K; Kinowaki Y; Kitagawa M; Kurata M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830205
[TBL] [Abstract][Full Text] [Related]
5. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethality and Cancer - Penetrance as the Major Barrier.
Ryan CJ; Bajrami I; Lord CJ
Trends Cancer; 2018 Oct; 4(10):671-683. PubMed ID: 30292351
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment.
Xing H; Meng LH
Acta Pharmacol Sin; 2020 May; 41(5):583-587. PubMed ID: 31792341
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
[TBL] [Abstract][Full Text] [Related]
11. [Individualization of anticancer therapy; molecular targets of novel drugs in oncology].
Regulska K; Stanisz B; Regulski M
Postepy Hig Med Dosw (Online); 2012 Nov; 66():855-67. PubMed ID: 23175342
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
13. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
14. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality screens point the way to new cancer drug targets.
Mullard A
Nat Rev Drug Discov; 2017 Sep; 16(9):589-591. PubMed ID: 28860588
[No Abstract] [Full Text] [Related]
16. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
17. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
Bao J; Qiao L
Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
[No Abstract] [Full Text] [Related]
18. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Behan FM; Iorio F; Picco G; Gonçalves E; Beaver CM; Migliardi G; Santos R; Rao Y; Sassi F; Pinnelli M; Ansari R; Harper S; Jackson DA; McRae R; Pooley R; Wilkinson P; van der Meer D; Dow D; Buser-Doepner C; Bertotti A; Trusolino L; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
Nature; 2019 Apr; 568(7753):511-516. PubMed ID: 30971826
[TBL] [Abstract][Full Text] [Related]
19. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
[TBL] [Abstract][Full Text] [Related]
20. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
